Get the Stockscreener App
7.50
0.52%
-0.19
Instil Bio Inc stock is traded at $7.50, with a volume of 5,967.
It is down -0.52% in the last 24 hours and up +7.29% over the past month.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.
See More
Previous Close:
$7.69
Open:
$7.71
24h Volume:
5,967
Relative Volume:
0.05
Market Cap:
$51.88M
Revenue:
-
Net Income/Loss:
$-74.14M
P/E Ratio:
-0.6585
EPS:
-11.39
Net Cash Flow:
$-65.70M
1W Performance:
+3.10%
1M Performance:
+7.29%
6M Performance:
-73.02%
1Y Performance:
-60.36%
1-Day Range:
$7.51
$7.8699
1-Week Range:
$7.15
$7.87
52-Week Range:
$5.67
$42.79
Instil Bio Inc Stock (TIL) Company Profile
Name
Instil Bio Inc
Sector
Industry
Phone
(972) 499-3350
Address
3963 MAPLE AVENUE, DALLAS
Compare TIL vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TIL
Instil Bio Inc
|
7.65 | 52.15M | 0 | -74.14M | -65.70M | -11.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.59 | 117.59B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
766.11 | 79.81B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
834.08 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.76 | 42.67B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
347.31 | 39.11B | 4.98B | 69.60M | 525.67M | 0.5198 |
Instil Bio Inc Stock (TIL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-07-26 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jan-06-26 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jan-07-25 | Upgrade | Jefferies | Hold → Buy |
| Nov-04-24 | Initiated | JMP Securities | Mkt Perform |
| Apr-12-24 | Downgrade | Jefferies | Buy → Hold |
| Nov-01-22 | Downgrade | Cowen | Outperform → Market Perform |
| Nov-01-22 | Downgrade | Truist | Buy → Hold |
| Aug-13-21 | Initiated | Robert W. Baird | Outperform |
| Apr-13-21 | Initiated | Cowen | Outperform |
| Apr-13-21 | Initiated | Morgan Stanley | Equal-Weight |
| Apr-13-21 | Initiated | Truist | Buy |
View All
Instil Bio Inc Stock (TIL) Latest News
Market Leaders: Is Instil Bio Inc gaining market shareBreakout Watch & Advanced Technical Signal Analysis - baoquankhu1.vn
(TIL) Volatility Zones as Tactical Triggers - Stock Traders Daily
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, ... - Bluefield Daily Telegraph
Price-Driven Insight from (TIL) for Rule-Based Strategy - Stock Traders Daily
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc.TIL - yourwyominglink.com
Bronstein, Gewirtz & Grossman, LLC Encourages Instil Bio, Inc. (TIL) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Instil Bio, Inc. (TIL) And Encourages Shareholders to Connect - accessnewswire.com
Entry Recap: Is TROOPS Inc benefiting from interest rate changesJuly 2025 Opening Moves & Target Return Focused Stock Picks - baoquankhu1.vn
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Instil Bio, Inc. (TIL) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
TIL ALERT: Ongoing Investigation Into Instil Bio, Inc.Contact Levi & Korsinsky - TMX Newsfile
Instil Bio Faces Investigation After AXN-2510 Discontinuation, Stock Plummets 45.81% - intellectia.ai
Bronstein, Gewirtz & Grossman, LLC Encourages Instil Bio, Inc. (TIL) Stockholders to Inquire about Securities Investigation - accessnewswire.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Instil Bio, Inc. (TIL) and Encourages Investors to Learn More About the Investigation - accessnewswire.com
(TIL) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Bronstein, Gewirtz & Grossman, LLC Is Investigating Instil Bio, Inc. (TIL) And Encourages Investors to Connect - accessnewswire.com
Forecast Cut: Can Instil Bio Inc scale operations efficientlyJuly 2025 Closing Moves & Technical Buy Zone Confirmations - baoquankhu1.vn
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AST SpaceMobile, Inc. - GlobeNewswire Inc.
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Instil Bio, Inc. (TIL) And Encourages Stockholders to Reach Out - accessnewswire.com
Published on: 2026-01-13 02:54:06 - ulpravda.ru
Instil Bio, Inc. (TIL) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - accessnewswire.com
Will Instil Bio Inc. stock see PE expansionJuly 2025 Drop Watch & Fast Entry Momentum Alerts - Улправда
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Instil Bio, Inc. (TIL) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Will Instil Bio Inc. stock benefit from green energy trendsMarket Risk Summary & Community Supported Trade Ideas - Улправда
Portfolio Update: Is Instil Bio Inc. stock a good choice for value investorsJuly 2025 Opening Moves & Daily Volume Surge Signals - Улправда
Citizens analyst reiterates Market Perform rating on Instil Bio stock By Investing.com - Investing.com South Africa
Why analysts remain bullish on Instil Bio Inc. stockMarket Entry Points & Low Risk Trading Portfolio - Улправда
Instil Bio (TIL) Downgraded to Neutral by HC Wainwright & Co. | TIL Stock News - GuruFocus
Instil On The Slide After PD-(L)1xVEGF Exit - Citeline News & Insights
Citizens analyst reiterates Market Perform rating on Instil Bio stock - Investing.com
Instil Bio ends license agreement with ImmuneOnco for AXN-2510 and AXN-27M - Investing.com Nigeria
Instil Bio Ends Key Oncology Licensing Agreement with ImmuneOnco - TipRanks
Instil Bio Terminates License and Collaboration Agreement With ImmuneOnco Biopharmaceuticals - TradingView — Track All Markets
Instil Bio shares slide on discontinuation of lead clinical programs - Proactive financial news
Baird downgrades Instil Bio stock to Neutral on AXN-2510 discontinuation By Investing.com - Investing.com South Africa
Baird downgrades Instil Bio stock to Neutral on AXN-2510 discontinuation - Investing.com Canada
Instil Bio Halts Main Drug Development Program - Bitget
US Stocks Mixed; Nasdaq Gains Over 50 Points - Benzinga
Instil's stock sinks after it clears out pipeline, hands 2 drugs back to ImmuneOnco - Fierce Biotech
Instil’s bispecific dream is over | ApexOncoClinical Trials news and analysis - Oncology Pipeline
Instil Bio stock falls after subsidiary discontinues AXN-2510 development By Investing.com - Investing.com Canada
Instil Bio stock falls after subsidiary discontinues AXN-2510 development - Investing.com
Instil Bio’s Subsidiary Discontinues Clinical Development of AXN-2510 and Terminates License and Collaboration Agreement with ImmuneOnco - The Manila Times
Instil Bio’s Subsidiary Discontinues Clinical Development - GlobeNewswire
(TIL) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
IPO Launch: How Zura Bio Limited stock valuations compare to rivalsNew Guidance & Consistent Income Trade Recommendations - moha.gov.vn
Insider Buy: How Instil Bio Inc stock performs after earningsChart Signals & Short-Term Trading Alerts - moha.gov.vn
Rally Mode: Why Instil Bio Inc. stock is favored by top institutionsJuly 2025 Review & High Accuracy Trade Alerts - Улправда
Instil Bio Inc Stock (TIL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Instil Bio Inc Stock (TIL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Laumas Sandeep | CFO and CBO |
Sep 10 '25 |
Sale |
23.39 |
30,000 |
701,667 |
0 |
3.02%
1.67%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):